Introduction {#S1}
============

The prevalence of liver diseases is rising, and they account for approximately 2 million deaths per year worldwide ([@B5]). The etiologies of chronic liver diseases are multifactorial and show variation according to geographical location ([@B136]). The main causes include chronic viral infections (hepatitis B and C), excessive alcohol intake, obesity-related fatty liver disease and steatohepatitis, inherited diseases (Wilson's disease, storage disorders, hepatorenal tyrosinemia, etc.), autoimmune liver diseases, drug-related liver diseases, as well as malignancies and idiopathic causes ([@B136]).

To date, various cell culture and animal models have been used to decipher the molecular mechanisms of liver development and pathogenesis. Among them, conventional two-dimensional (2D) cell cultures have several limitations, especially for long-term and stable expansion. In addition, 2D primary hepatocyte cultures fail to replicate key aspects of the human liver tissue, in particular, the complex architecture and cellular heterogeneity ([@B32]; [@B101]). Moreover, these cells often lack cell--cell and cell--extracellular matrix (ECM) interactions that are essential for maintaining *in situ* phenotypes and biological functions as well as tissue-specific cellular processes ([@B9]; [@B32]). Furthermore, primary hepatocytes have limited division capacity when grown in 2D cultures and rapidly lose liver-specific gene expression patterns and functions, such as the synthesis of coagulation inhibitors ([@B14]), maintenance of stable cytochrome P450 ([@B26]; [@B65]), and integrin ligation ([@B80]), at a few weeks after plating ([@B22]; [@B11]; [@B84]).

Ever since induced pluripotent stem cell (iPSC) technology was established, hepatocyte generation by stepwise differentiation protocols that mimic *in vivo* organogenesis has become readily feasible in 2D cultures ([@B116]; [@B112]; [@B20]; [@B49]). These protocols typically use cocktails of growth factors/cytokines in order to recapitulate embryonic liver development under *in vitro* culture conditions. Nevertheless, the hepatocytes derived by these differentiation protocols vary considerably in their maturation level and, in most cases, represent immature hepatocytes. Plus, they do not have the ability to expand for the long term in monolayer culture, partly due to the absence of a tissue-specific architecture, mechanical and biochemical cues, and cell--cell communications under 2D conditions ([@B93]; [@B73]).

Animal models can also be used in the study of liver pathologies. The large majority of these models have functional vasculature, stromal, and immune components, offering numerous benefits over 2D cultures. However, animal models need resource-intensive and time-consuming processes to be developed. Furthermore, physiological and genomic interspecies differences in animal models pose limitations in the representation of the disease phenotypes and the prediction of research outputs such as drug response ([@B75]).

Organoids are simply defined as 3D cell culture systems that mimic the structural and functional characteristics of the represented organ. This definition refers to the assembly of organ-specific cell type(s) that develop from pluripotent stem cells/organ stem/progenitor cells and their self-organization through cell sorting and spatially restricted lineage commitment, similar to the developmental process *in vivo* ([@B68]; [@B23]; [@B37]). Organoid structures can be stably maintained in long-term *in vitro* cultures, continuing to reflect, even after many generations, the *in vivo* characteristics of the tissue of origin without any significant genetic or physiological changes ([@B55]; [@B2]). During the process of organoid culture, often in a tissue-specific manner, a number of growth factors and small molecules are utilized in order to regulate the signaling pathways that are essential for the self-renewal, differentiation, and proliferation of organoids. At present, two main approaches to successfully forming organoids using defined biochemical factors in a proper 3D matrix have been widely exploited. The first approach is based on the differentiation of pluripotent stem cells (PSCs), which then self-organize to form tissue-specific organoids such as the optic cup ([@B34]; [@B86]; [@B67]; [@B35]), brain ([@B69]; [@B94]), intestine ([@B113]), pancreas ([@B43]), liver ([@B119]; [@B103]; [@B47]; [@B70]; [@B2]; [@B63]), lung ([@B33]), prostate ([@B30]), kidney ([@B117]), and blood vessel ([@B130]). The second approach relies on the derivation of functional organoids from tissue-specific adult/fetal/pediatric stem or progenitor cells, which preserve, under normal and damaged conditions, the regenerative capacity of specific tissues. These types of organoids have also been established from multiple tissues including intestine ([@B91]; [@B104]), stomach ([@B8]), liver ([@B55]; [@B52]), kidney ([@B109]), skin ([@B13]), and pancreas ([@B53]; [@B12]).

Liver {#S2}
=====

Structure and Function {#S2.SS1}
----------------------

The liver, the largest organ in the body, serves vital metabolic, exocrine, and endocrine functions. In addition to bile production and regulation of glycolytic, urea, and cholesterol metabolism, the liver promotes blood detoxification and regulates blood homeostasis, particularly by secreting coagulation factors and serum proteins such as albumin ([@B42]; [@B114]). The liver lobule, composed of heterogeneous cell types, is the smallest structural unit of the liver. Metabolically, it is divided into different structural zones and functional organizations ([@B61]). Hepatocytes are the major parenchymal cell type of the liver lobules, accounting for ∼70% of the total mass of an adult organ. Hepatocytes and cholangiocytes (the other epithelial cell type of the liver) are derived from the embryonic endoderm, while the non-parenchymal liver cells, such as the stromal cells, stellate cells, Kupffer cells, and blood vessels, have a mesodermal origin ([@B42]; [@B114]). Recent advanced technologies, in particular, single-cell RNA sequencing, have made it possible to identify the existence of adult human liver-resident epithelial progenitors and to map stem/progenitor heterogeneity within the liver. These new insights have provided strong guidance cues for advancing understanding of liver biology and physiology ([@B1]).

Liver Organogenesis {#S2.SS2}
-------------------

The main principle of liver organoid technology is to recapitulate the major phases of organogenesis in a dish. An understanding of sequential events and regulatory factors in liver development is therefore crucial ([@B121]; [@B111]; [@B38]). During gastrulation, blastula first gives rise to endoderm (one of the three primary germ layers), which is further patterned into discrete organ domains in the foregut, midgut, and hindgut. The liver bud is then formed from the foregut endoderm by the induction of Activin/Nodal, WNT, FGF, and BMP signals ([@B29]; [@B46]; [@B58]; [@B59]; [@B100]; [@B133]; [@B25]; [@B48]). Following the formation of this structure, the hepatoblasts undergo expansion and differentiation to yield both hepatocytes and biliary epithelium, while the adjacent mesoderm-derived mesenchyme contributes to the generation of liver fibroblasts and stellate cells. The normal structure of the liver tissue is then completed by further maturation of the hepatocytes and cholangiocytes and the cellular integration of the mesenchyme and endothelium ([@B121]).

Organoid Models {#S3}
===============

iPSC-Derived 3D Liver Organoid Models {#S3.SS1}
-------------------------------------

### Hepatic Organoids {#S3.SS1.SSS1}

The generation of hepatic organoids from iPCSs was first proposed by Takebe and colleagues using an elegant co-culture model. In this model, hepatic progenitors were obtained by stepwise differentiation from iPSCs in a 2D cell culture setting and then co-cultured with human mesenchymal stem cells (MSCs) and Human Umbilical Vein Endothelial Cells (HUVECs). Subsequently, macroscopically visible 3D aggregates called iPSC-liver buds (LB) were spontaneously produced in a Matrigel-embedded culture. Furthermore, human vasculature structures in iPSC-LB became functional by connecting to the host vessels following transplantation. In particular, the hepatic cells in the engrafted liver buds started to secrete albumin into the bloodstream of the recipient mouse from day 10 until day 45 post-transplantation. More importantly, these organ bud structures demonstrated an ability to regenerate and rescue drug-induced lethal liver failure ([@B119]). In a follow-up study, single-cell RNA sequencing elucidated patterns of gene expression unique to lineage identity and facilitated identification of heterogeneous and dynamic cell populations during differentiation from pluripotency to a liver bud ([@B18]; [@B98]). Following these efforts on generating a functional human liver bud, many research groups have developed various protocols to produce different types of liver organoids derived from pluripotent stem cells. Some of the important protocols in the field are summarized in [Figure 1](#F1){ref-type="fig"}.

![Key protocols for generating iPSC-derived 3D liver organoid cultures. FCS, Fetal Calf Serum; 3D, three-dimensional; FGF, Fibroblast Growth Factor; TGF, Transforming Growth Factor; R-SPO, R-Spondin; EGF, Epidermal Growth Factor; HGF, Hepatocyte Growth Factor; CM, Condition Medium; FACS, Fluorescence-Activated Cell Sorting; EpCAM, Epithelial Cell Adhesion Molecule; iPSC, Induced Pluripotent Stem Cell; BMP, Bone Morphogenetic Protein; ME, Mesoendoderm; HP, Hepatic Progenitor; KGF, Keratinocyte Growth Factor; HB, Hepatoblast; HCM, Hepatocyte Culture Medium; OSM, Oncostatin M; H/C, Hepatocyte/Cholangiocyte; Dex, Dexamethasone; ITS, Insulin-Transferrin-Selenium; DE, Definitive Endoderm; FG, Foregut; FP, Foregut Progenitor; CP, Cholangiocyte Progenitor.](fcell-07-00345-g001){#F1}

[@B47] have recently established iPSC-derived hepatic organoids (Hep-org), surrounded by cholangiocyte ductal structures, within about 50--60 days. Unfortunately, when these organoids reached a critical size, making it difficult to receive enough nutrients and oxygen, their proliferation and regenerative capacity decreased significantly. This disadvantage was overcome by dissociating the organoids into single cells and then replating and reforming them in Matrigel ([@B47]). Recently, a new protocol has been described for the generation of human pluripotent stem cell (hPSC)-derived organoids with a hepato-biliary structure. The organoids displayed hepatic gene expression signatures and key functional characteristics of cholangiocytes *in vitro* and survived more than 8 weeks after transplantation in immune-deficient mice ([@B131]).

More recently, we described a rapid and highly efficient protocol for the production of human hepatic organoids derived from iPSCs. Our study revealed that enrichment of Epithelial Cell Adhesion Molecule (EpCAM)-positive cells resulted in a homogenous population of endodermal cells and licensed the differentiation of functional hepatocytes. In addition, R-Spondin improved the specification of EpCAM-positive endoderm intermediate cells in this culture system ([@B2]). Moreover, only EpCAM-positive endodermal cells, and not EpCAM-negative cells, had the ability to form hepatic organoids. Our findings are in strong agreement with previous studies showing that EpCAM exhibited a dynamic pattern of gene expression during liver development and that EpCAM-positive cells were able to give rise to liver compartments ([@B107]; [@B120]; [@B72]). In addition, our study showed that these endoderm-derived hepatic organoids (dubbed eHEPOs) could be produced in 14 days and expanded for more than 1 year without any significant loss in culturing efficiency ([@B2]). Likewise, *in vitro* characterization analyses indicated that eHEPOs could obtain epithelial morphology and a pseudostratified structure. One of the key aspects of this method was that the cellular composition and the morphological structure of eHEPOs were preserved in young and old organoids. Furthermore, analysis of gene expression profiles revealed a transition from pluripotency toward mature hepatocytes. Finally, eHEPOs exhibited functional characteristics of mature hepatocytes *in vitro*, efficiently engrafted in the mouse liver, and expressed human ALB at day 32 following intrasplenic injection ([@B2]). More recently, a breakthrough method has been developed to establish an integral multi-organ structure. First, the anterior and the posterior gut spheroids were separately differentiated from iPSCs. Afterward, an anterior spheroid was transferred to an adjacent posterior spheroid. Over time, these spheres fused and invaginated as an interconnected multi-organ. In sum, that method demonstrated that anteroposterior interaction recapitulated the foregut--midgut boundary *in vitro*, even in the absence of extrinsic factors ([@B63]).

### Cholangiocyte Organoids {#S3.SS1.SSS2}

Another type of organoids that exhibit cholangiocyte characteristics and functions were developed and used by several research groups to specifically study biliary duct physiology and cholangiopathies. For the first time, [@B27] have successfully generated iPSC-derived cholangiocyte-like cells (CLCs) in 3D culture. These cells displayed structural and functional similarity to primary cholangiocytes, such as cilia formation and response to hormonal stimulation. Similarly, CLCs were able to transport Rhodamine 123 into the lumen by the multidrug resistance 1 transmembrane (MDR1), another property of physiologically functional cholangiocytes ([@B27]). Then, by combining 2D monolayer and 3D culture systems, Ogawa and colleagues generated cholangiocyte organoids (Chol-org) from hPSCs. This method utilized cholangiocyte development cues to establish a self-organized bile duct-like structure. Cholangiocyte fate was achieved using 3D co-culture of hepatoblasts with OP9 stromal cells in the presence of growth hormones. Herein, NOTCH protein secreted by OP9 cells was used to mimic JAG1/Notch signaling and promote cholangiocyte development and specification. The cholangiocytes exhibited a branching morphology and cholangiocyte-related gene expression profiles. Furthermore, these cells lost the expression of hepatoblast and hepatocyte markers such as Alpha-fetoprotein (AFP) and albumin. Transport activity assay and a forskolin-induced cyst swelling test verified the functionality of these cholangiocytes ([@B89]). Another approach developed by [@B103] demonstrated that Chol-org could be generated from hepatoblast-derived cholangiocyte progenitors using FGF10, Activin A, retinoic acid, and EGF. These Chol-org demonstrated functional properties of cholangiocytes such as alkaline phosphatase and gamma-glutamyl-transpeptidase activity as well as bile acid uptake and export ([@B103], [@B102]). Additionally, the use of laminin as a matrix increased the number and diameter of cysts as well as the expression of iPSC-derived cholangiocyte marker genes ([@B118]).

Adult Stem Cell-Derived 3D Liver Organoid Models {#S3.SS2}
------------------------------------------------

The liver displays a remarkable regenerative capacity ([@B83]; [@B51]; [@B114]). However, the types of cells involved in liver homeostasis and regeneration after damage are not well-defined. Previously, it was shown that Sox9-positive cells (oval cells) near the bile duct participate in the regenerative response of the liver after massive injury ([@B41]). Such findings are in close agreement with other studies that highlighted the contribution of biliary epithelial cells to the regenerative response of the liver ([@B28]; [@B36]). Likewise, the results of these studies are consistent with other findings demonstrating that ablation of hepatic progenitors impairs liver regeneration ([@B110]). Collectively, these findings indicate that liver stem/progenitor cells retain the potential to form the liver parenchyma *in vivo* and organoids *in vitro*.

The available evidence suggests that Lgr5-positive progenitor cells are not present in the healthy adult liver and pancreas ([@B54]), but, rather, they are activated upon chemical damage and become detectable near the bile ducts of the liver. It has been shown that freshly isolated healthy bile duct fragments and, more intriguingly, Lgr5-positive single cells isolated from mouse liver could yield 3D organoids. These bipotent epithelial liver organoids could be differentiated into mature and functional hepatocytes *in vitro* and could rescue liver failure in the fumarylacetoacetate hydrolase (*Fah*−/−) mutant mouse, a model for tyrosinemia type I liver disease, after transplantation ([@B54]; [@B16]). Furthermore, the Clevers group adapted a mouse liver organoid protocol to culture bipotent stem cells from the adult human liver ([@B55]). They demonstrated that human EpCAM-positive single cells from the ductal area or even ductal fragments could develop into clonal epithelial hepatic organoids. These organoids could generate functional hepatocytes after differentiation *in vitro* and engraftment within the parenchyma of recipient mouse liver *in vivo*. The study also found that the organoids were genetically stable in long-term cultures, being characterized by a low number of single base changes, most of which were probably incorporated before or during organoid generation but not during culture ([@B55]). Although Huch's model elegantly demonstrated that the ductal progenitors had the capacity to generate hepatocytes under defined culture conditions and Raven and collaborators have more recently shown that impaired hepatocellular regeneration during liver injury could trigger ductular reaction and the generation of hepatocytes of non-hepatocyte origin ([@B99]), there is an ongoing controversy surrounding studies that demonstrated that the majority of regenerative response following hepatic damage rely primarily on hepatocytes rather than stem cells ([@B44]). In particular, murine lineage-tracing studies provided supporting evidence that only hepatocytes were involved in liver regeneration after damage ([@B105]; [@B132]). Wnt signaling from liver endothelial cells can influence homeostatic self-renewal of hepatocytes. Specialized Axin2-positive cells localized to the pericentral liver lobule were previously identified as the source of precursors for this homeostatic reaction ([@B127]). The expression of early liver progenitor marker TBX3 in these cell types confirmed the presence of a mature and progenitor cell population in the adult liver. Likewise, periportal and hybrid hepatocytes with low levels of SOX9 expression replenished the liver mass after chronic injury ([@B39]). Accordingly, the Clevers group has recently established a new organoid model originating from a single mature Axin2-positive hepatocyte. Their study showed that Wnt/Rspo1 and HGF signaling pathways were the main regulators of primary hepatocyte expansion in both mouse and human organoid models. This approach facilitated the growth of hepatic organoids from a single hepatocyte directly after collagenase digestion. Here, both undamaged hepatocytes and hepatocytes from physically damaged liver (partial-hepatectomy, PHx) were used for the production of murine hepatic organoids. These organoids displayed the key functional attributes and gene expression profiles of hepatocytes. In addition, Gene Set Enrichment Analysis (GSEA) of PHx-derived organoids revealed that the gene expression profiles of mouse hepatic organoids resembled those of post-PHx proliferating hepatocytes. Accordingly, hepatic organoids recapitulated the regenerative response of adult liver upon partial hepatectomy. Fetal and adult human liver specimens were also used to form organoids in the same study. When compared to adult donors' hepatic organoids, fetal-derived hepatic organoids displayed higher expansion capacity. One reason for impaired expansion in the adult hepatic organoids could be the inherently limited activity of telomerase enzyme ([@B52]). Moreover, the low number of cholangiocytes inside the hepatic organoids and trans-differentiation of Hep-org to Chol-org when cultured in cholangiocyte medium ([@B55]) is a sign of *de novo* generation of bile ducts after partial resection. Hepatic organoids, in this study, were different from the earlier Chol-org models in terms of cell size, nucleus/cytoplasm ratio, subcellular structure and function, and gene expression profiles. This critical difference could be explained by the cell of origin of the organoids. While the hepatic organoids originated from hepatocytes, Chol-org were developed from EpCAM-positive precursor cells. Moreover, in terms of *in vivo* functionality, the same study showed that organoids were able to engraft and repopulate in the liver of immunodeficient mice ([@B52]).

Complex crosstalk between hepatocytes, plasma, and other resident cells in the liver plays a key role in maintaining liver functions and regulating regenerative responses. Autocrine signals from hepatocytes (VEGF, TGF-α), paracrine signals from stellate cells (HGF) ([@B82]), and inflammatory cytokines from Kupffer cells (IL-6 and TNF-α) are essential for triggering a successful liver regenerative reaction. [@B95] have recently shown that TNF-α would promote mouse hepatocyte expansion in 3D culture conditions *in vitro*. Also, these cells were able to engraft and repopulate in *Fah*−/− mouse liver. Based on these findings, one can conclude that this approach could potentially be integrated with Hu's protocol for the generation of human hepatocytes with near-physiological features. Another liver organoid culture model has been developed by [@B126]. Herein, decellularized ferret liver scaffolds were seeded with human fetal progenitor cells containing liver stromal and endothelial cells and then incubated in differentiation media for 3 weeks to induce hepatobiliary organoids in an *in vitro* culture setting. Although this model proved that hepatic and biliary lineage specification and maturation in scaffold was better than for the cells grown in Matrigel, the self-renewal capacity of the organoids and efficiency of this method in recapitulating adult liver functions was comparably low ([Figure 2](#F2){ref-type="fig"}).

![Key protocols for developing adult liver stem cell-derived 3D liver organoid cultures. 3D, three-dimensional, FGF, Fibroblast Growth Factor; TGF, Transforming Growth Factor; R-SPO, R-Spondin; EGF, Epidermal Growth Factor; HGF, Hepatocyte Growth Factor; CM, Condition Medium; FACS, Fluorescence-Activated Cell Sorting; EpCAM, Epithelial Cell Adhesion Molecule.](fcell-07-00345-g002){#F2}

3D Organoid Models for Non-parenchymal Liver Cells {#S3.SS3}
--------------------------------------------------

Hepatic stellate cells (HSCs) are liver-specific mesenchymal cells that contribute to liver physiology and pathophysiology ([@B108]; [@B79]; [@B129]). In a healthy liver, HSCs are quiescent at baseline, and their function is to store vitamin A lipid droplets. Following damage due to toxins or viral infections, HSCs become metabolically active resulting in the accumulation of ECM in liver ([@B40]). HSCs have limited proliferation capacity in 2D culture, cannot maintain the quiescent phenotype, and spontaneously lose key functional features *in vitro* ([@B78]; [@B96]). [@B66] showed that iPSC-derived HSC progenitors could be expanded and maturated *in vitro* and could acquire lineage-specific characteristics. A recent study by [@B24] has established an efficient culture system to differentiate HSCs from iPSCs. In this system, HSCs were generated via protocols that were initially developed to establish HSCs from ESCs ([@B4]; [@B90]). Briefly, iPSCs were differentiated toward mesodermal progenitors with BMP4. Then, these mesothelial cells were induced with retinol and palmitic acid for their subsequent differentiation into HSCs. After 12 days, the resulting cells resembled primary HSCs in terms of morphology, transcriptome profile, and functional attributes. In addition, when grown as 3D spheroid co-cultures together with HepaRG cells, HSCs stored vitamin A and, more importantly, they switched from a quiescent state to an activated state in response to hepatic toxicity. In conclusion, this method provided a robust and reliable culture system for the investigation of liver biology and pathobiology using hepatic organoids and activated HSCs ([@B24]).

Potential Applications of Liver Organoids {#S4}
=========================================

Organoids have many great advantages over conventional cell culture techniques. These miniaturized organs enable long-term stable expansion in a near-physiological manner and mimic 3D tissue function and structure and disease pathology. Therefore, they have tremendous potential to be transformed into excellent platforms for various basic and translational research applications, including disease modeling, drug screening, gene therapy, elucidating microbe-host interactions, and organ replacement ([Figure 3](#F3){ref-type="fig"}).

![Potential applications for liver organoids.](fcell-07-00345-g003){#F3}

Disease Models via Liver Organoids {#S4.SS1}
----------------------------------

Over the past few years, with the discovery of other powerful technologies, CRISPR-Cas9 genome editing in particular, organoids research has opened up new avenues for understanding the molecular pathophysiology of diseases. To this end, the introduction of disease-specific mutations into the liver organoids derived from healthy donors has become rapid and seamless, enabling researchers to readily investigate mutation-related mechanisms and clinical phenotypes. Alternatively, tissue explants or biopsies from patients can also be used directly for the production of disease-specific organoids. [Table 1](#T1){ref-type="table"} summarizes the liver disease models published in the literature.

###### 

Organoid-based liver disease models.

  **Organoid type**   **Cell source**      **Disease**                                    **Modeling approach**   **References**   
  ------------------- -------------------- ---------------------------------------------- ----------------------- ---------------- ---------
  Hepatic             Liver Biopsy         A1-Antitrypsin Deficiency, Alagille Syndrome   ✓                                        [@B55]
  Tumor               Surgical Resection   Liver Cancer                                   ✓                                        [@B17]
  Tumor               Needle Biopsy        Liver Cancer                                   ✓                                        [@B88]
  Tumor               Surgical Resection   Liver Cancer                                   ✓                                        [@B71]
  Hepatic             iPSCs                Alagille Syndrome                              ✓                       ✓                [@B47]
  Hepatic             iPSCs                Citrullinemia type I                           ✓                                        [@B2]
  Hepatic             iPSCs                Steatohepatitis Wolman Disease                 ✓                                        [@B92]
  Cholangiocyte       iPSCs                Cystic Fibrosis                                ✓                                        [@B89]
  Cholangiocyte       iPSCs                Cystic Fibrosis                                ✓                                        [@B103]

### Rare and Genetic Diseases {#S4.SS1.SSS1}

Alpha-1-antitrypsin deficiency (A1ATD) is a rare inherited disorder that causes lung and liver diseases, skin problems, and inflammation of the blood vessels. A1AT is a serine protease inhibitor that is synthesized mostly in the liver and transferred through the bloodstream to the lungs. Its primary function in the lungs is to inhibit an enzyme called neutrophil elastase, thus protecting the lung tissue against proteolytic degradation. The most common genetic missense mutation in A1ATD is the PiZ allele (Glu^342^Lys) of the SERPINA1 gene, which results in the agglomeration of misfolded proteins in hepatocytes ([@B7]). To model this condition, [@B55] developed organoids using liver biopsy specimens obtained from three patients with A1ATD disease. Notably, patient-derived organoids (PDO) mimicked the disease pathology, with reduced protein levels and aggregation of A1AT protein in the endoplasmic reticulum. Alagille syndrome (ALGS), another multisystem genetic disorder, was also modeled using the same approach ([@B55]). Of note, ALGS has autosomal dominant inheritance and is predominantly caused by heterozygous mutations in the JAG1 gene, which codes for the Jagged1 protein, a transmembrane ligand in the Notch signaling pathway. JAG1 mutations lead to deficiencies in various tissues, including liver, heart, and muscle ([@B122]). According to the findings of this study, organoids from ALGS patients were unable to form intact bile duct structures *in vitro*, and cells in the organoid lumen underwent apoptosis, mimicking the *in vivo* disease pathology ([@B55]). In addition to liver stem/progenitor-derived organoids, Guan and colleagues used patient-specific iPSCs to model this genetic disorder. Specifically, iPSCs from two ALGS patients were differentiated into organoids via the protocol described in [Figure 1](#F1){ref-type="fig"}. In contrast to healthy organoids, the bile duct formation and the biliary transport function of ALGS-specific PDOs were significantly impaired. In addition, using a reverse approach employing CRISPR-Cas9 technology, ALGS-causing JAG1 mutation C829X was introduced into iPSCs prepared from healthy human fibroblasts. As a result, the capacity of the genetically modified iPSC-derived organoids to form duct-like structures was significantly reduced, recapitulating the ALGS liver pathology ([@B47]).

Citrullinemia type I (CTLN1) is an inherited urea cycle disorder of the liver arising from a deficiency in the enzyme Argininosuccinate Synthase 1 (ASS1) ([@B64]). Infant patients with severe Citrullinemia type I experience life-threatening clinical manifestations, such as episodes of hyperammonemia that might be fatal or result in permanent neurologic damage. Current strategies (drugs and a low-protein diet) for the management of Citrullinemia type I are not effective, and, in severe cases, long-term survival is low. Cell transplantation with functional hepatocytes emerges as a promising therapeutic approach. Recently, iPSCs derived from Citrullinemia type I patients with homozygous G390R mutations in the ASS1 gene have been used to develop a disease-specific model. Particularly, patient-specific iPSCs were generated by reprograming dermal fibroblasts with episomal vectors and differentiating toward definitive endoderm under defined conditions. Then, iPSC-derived EpCAM-positive endodermal cells were isolated and used to generate functional hepatic organoid cultures. These organoids exhibited hepatocyte-specific marker gene expression and recapitulated the key metabolic functions of mature hepatocytes, including LDL uptake, albumin secretion, and glycogen storage. Further analysis revealed that the hepatic organoids mimicked the clinical phenotypes of Citrullinemia type I patients such as increased ammonia and decreased urea. Moreover, these phenotypes could be rescued by ectopic expression of the wild-type ASS1 gene in patient-derived organoids. Collectively, this model offers a promising framework to study gene correction/replacement strategies in cell-based therapies and perform pre-clinical drug discovery and development studies in urea cycle disorders ([@B2]).

Cholangiocyte organoids derived from iPSCs have also been used for disease modeling. For instance, Ogawa and colleagues, as described in [Figure 1](#F1){ref-type="fig"}, used patient-specific Chol-org for modeling the Cystic Fibrosis (CF) disease. CF is a life-threatening rare autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Mutations in the CFTR gene disrupt the function of the chloride ion channel, causing dysregulation of ion flux and epithelial fluid transport in the lung, pancreas, colon, and liver. In this study, Chol-org derived from iPSCs displayed misfolded CFTR proteins, impaired cyst formation, and loss of chloride channel function, reflecting the disease phenotype of the patients. Furthermore, they showed that exposure of the organoids to a small-molecule CFTR potentiator drug VX-770 (Ivacaftor) along with forskolin and IBMX corrected the misfolding defect and led to the functional restoration of the mutant CFTR protein ([@B89]). Chol-org were also used in another study to successfully model ALGS, polycystic liver disease, and CF-associated cholangiopathy ([@B103]). Particularly, the treatment of patient-derived Chol-org with CF-related drugs (verapamil and octreotide) rescued the clinical phenotype of CF cholangiopathy *in vitro*. In support of these findings, an ongoing research project called HIT-CF Europe^[1](#footnote1){ref-type="fn"}^ is also using next-generation cell culture systems with the aim of evaluating the efficacy and safety of rare CF mutation-specific drug candidates in patient-derived organoids. The project highlights the exciting promise of organoid culture systems to provide better lives for people with CF. Taken together, next-generation organoid technologies hold great potential to accurately model biliary-related diseases and pave the way for organoid-based preclinical studies in precision medicine.

### Cancer and Complex Diseases {#S4.SS1.SSS2}

Liver cancer is the fifth most common cancer in the world and the second leading cause of death ([@B15]). The lack of powerful liver cancer models that accurately recapitulate the histopathology, heterogeneity, genome and transcriptome profile of tumors hampers the development of effective treatments. While different liver cancer models, such as cancer cell lines and patient-derived xenografts (PDX), have been established in the past, the drawbacks of each model limit their applications in liver cancer studies. For instance, when passaged for long periods in 2D culture, the cancer cell lines accumulate mutations and undergo clonal selection, which results in loss of original genetic and phenotypic heterogeneity ([@B62]). Moreover, the low engraftment rate, high cost, time-consuming nature of establishment, and non-suitability for large-scale drug testing limit the use of PDX models ([@B50]; [@B45]; [@B19]).

Personalized cancer medicine is a novel and innovative approach aiming to establish effective therapeutic strategies for each patient based on tumor-specific features. In this regard, tumor organoids called tumoroid models are emerging as a promising platform. Recently, Broutier et al. established a tumoroid culture model from three different subtypes of primary liver cancer (PLC), namely hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined hepatocellular-cholangiocarcinoma (CHC), using liver cancer samples obtained from patients with no history of viral treatment. The established tumoroids retained the histological characteristics as well as transcriptome profiles and genomic signatures of the original tissue. Furthermore, *in vivo* studies demonstrated the tumorigenic and metastatic potential of PLC-derived organoids upon transplantation under the kidney capsule. Importantly, integrated omics data from PLC-derived organoids led the researchers to identify new biomarkers and novel potential therapeutic agents for PLC, such as an ERK inhibitor ([@B17]). In another study, [@B88] developed a methodology through which they generated tumoroids from needle biopsy samples from different HCC patients with various tumor stages and etiologies. These tumoroids successfully recapitulated the histopathological properties along with the gene expression profiles and mutational landscapes of the original tissues. Moreover, they also preserved tumor features after transplantation into immunodeficient mice ([@B88]).

Recently, [@B71] have developed a cohort of 27 tumoroid cell lines from multiple regions of human tumor samples from CC and HCC patients. Epithelial, bile duct, stemness, and mucin markers were used for the characterization of the cellular identity of tumoroids. Further analysis demonstrated that the patient-derived tumoroids reflected the histological features, transcriptome profiles and genetic background of the original primary liver tumors. Interestingly, high-throughput drug screening of these tumoroids displayed heterogeneous drug responses, suggesting strong intra- and inter-tumor heterogeneity. As a result, only a small group of drugs was found to be effective in blocking their proliferation ([@B71]).

With regard to liver cancer research, a new study demonstrated that organoid technology could be utilized to model cancer initiation ([@B115]). Specifically, Sun and colleagues suggested that direct reprograming of fibroblasts into 3D hepatocytes could be accomplished by ectopic expression of FOXA3, HNF1A, and HNF4A. Intriguingly, these hepatic organoids had limited expansion and proliferation capacity, which could be overcome by SV40 transduction. In this model, c-MYC transduction facilitated HCC initiation and liver cancer formation *in vivo*, in part through the induction of excessive mitochondrion-endoplasmic reticulum coupling. Furthermore, when transplanted orthotopically, RAS-transformed organoids formed intra-hepatic cholangiocarcinomas with a hepatocyte origin ([@B115]).

Organoids derived from normal tissues can also be used to model cancer by sequential introduction of cancer driver gene mutations. The advantage of using such models is they enable investigation of the effects of driver mutations in an isogenic (identical) genetic background. To this end, different laboratories have independently engineered mutant colon organoids by incorporating mutations for at least four of the most commonly altered genes in colorectal carcinoma, namely KRAS, APC, TP53, SMAD4, and PIK3CA ([@B31]; [@B77]). These mutant organoids developed adenocarcinomas when transplanted into the kidney capsule of recipient mice, modeling the progression of colon cancer. Similarly, a recent study has revealed that BAP1 loss-of-function by CRISPR-Cas9 in liver organoids, in combination with common cholangiocarcinoma mutations (TP53, PTEN, SMAD4, and NF1), affects epithelial tissue organization and cell-to-cell junctions and results in the acquisition of malignant features ([@B3]).

The potential of human liver organoids as a model for studying chronic and complex liver diseases is also promising for the discovery of effective treatments. In that regard, [@B92] have developed a method to generate a multi-cellular liver organoid system in order to model non-alcoholic steatohepatitis. In particular, the liver organoids exhibited lipid accumulation, fibrosis, and inflammation upon free fatty acid exposure. The findings of this study suggest that this system could recapitulate the progressive aspects of steatohepatitis and model Wolman disease and, more importantly, that FGF19 could be used to alleviate the disease pathologies ([@B92]).

Host--Microbiome Interactions {#S4.SS2}
-----------------------------

Randall's laboratory has studied Hepatitis C Virus (HCV) entry and localization in hepatoma organoids. HCV colocalizes in basolateral membrane, and its virions progressively accumulate at tight junctions. This model is a promising tool for investigating the complex traffic processes of HCV ([@B6]). Recently, Taniguchi's laboratory generated functional human iPSC-derived liver organoids and infected them with the Hepatitis B Virus (HBV) genome. Herein, the functional liver organoids demonstrated higher susceptibility to HBV infection than human iPSC-derived 2D hepatic-like cells and could maintain HBV propagation and produce infectious virus for longer durations. Notably, HBV infection resulted in severe hepatic dysfunction of organoids, characterized by elevated hepatic injury markers and an altered hepatic ultrastructure. Interestingly, this study also showed that HBV-infected liver organoids generated without the immune cells had an impaired hepatic function and thus proposed the hypothesis that HBV might indeed be a cytopathic virus ([@B87]).

In summary, liver organoids are highly promising models for studying hepatitis virus-host interactions and can easily become personalized infection models for individualized hepatitis studies and treatments.

Omic Profiling {#S4.SS3}
--------------

Instead of screening from established drug libraries, omics data can be used to predict novel drug candidates for diseases. With the help of organoid technology, one could also amplify sufficient quantities of healthy and diseased tissues *in vitro* and analyze causal mutations by deep sequencing or track treatment regimens by phenotypic profiling of the organoids using omic platforms. Recently, Huch's team has predicted novel drug targets for liver cancer patients by studying the omic profiles of tumoroids and showed that ERK inhibitors could decrease tumor formation in patient-derived xenograft models ([@B17]). These findings indicate that omic profiling would offer a convenient strategy to understand the molecular pathogenesis of diseases and identify novel therapeutic drug targets.

Bioengineered Organoid Models {#S4.SS4}
-----------------------------

To increase the longevity and reproducibility of cell functions *in vitro*, the research community is now using multiple bioengineering tools such as high-throughput microarrays, lab-on-chip technologies ([@B97]; [@B10]), protein micropatterning, microfluidics, specialized plates, biomimetic scaffolds, and bioprinting to control the cellular microenvironment ([@B135]). [@B123] have recently reviewed the advances in bioengineered liver models with utility in drug screening and the microenvironmental determinants of liver cell differentiation/function ([@B76]; [@B134]).

[@B57] developed a vascularized 3D liver organoid model derived from induced hepatocytes (iHep) that were directly differentiated from fibroblasts. They achieved this by co-culturing the iHeps with endothelial cells in a decellularized 3D liver extracellular matrix (LEM) hydrogel in a microfluidic-based cell culture device with a continuous dynamic flow of media. By taking advantage of this platform, iHep-based 3D liver organoids were able to establish a multiorgan system comprised of multiple organoids derived from different internal organs and demonstrated great feasibility for functional and standardized high-throughput drug screening (HTS) ([@B57]).

Micro-scale technologies can mimic *in vivo*-like cellular microenvironments by allowing precise control of crucial physicochemical factors such as fluid flow, biochemical signals, and so on ([@B56]; [@B106]; [@B21]). Recently, [@B128] proposed a simple and robust strategy that promoted *in situ* differentiation, long-term 3D culture, and the generation of hiPSC-based functional liver organoids in a perfusable micropillar chip system. The liver organoids displayed favorable growth and cellular heterogeneity characteristics involving the differentiation of hepatocytes and cholangiocytes, mimicking liver tissue *in vivo*. In particular, the liver organoids under perfused culture conditions exhibited improved cell viability as well as endoderm- and mature hepatocyte-specific gene expression. Moreover, when compared to static cultures, they displayed enhanced metabolic capabilities and liver-specific functions including albumin and urea production. Finally, the liver organoids showed a dose- and time-dependent hepatotoxic response to acetaminophen, which again offers an ideal platform for drug testing ([@B128]).

Hepatotoxicity {#S4.SS5}
--------------

Hepatotoxicity refers to the toxic effects of drugs and their metabolites on liver tissue and usually implies chemical-driven acute liver injury and failure. Toxicity analysis for all kinds of drugs is essential prior to their approval for entry into the market ([@B60]). Up to now, 2D primary hepatocytes have been used as a model for drug metabolism and toxicity screening. However, hepatocytes are unstable and functionally ineffective in long-term cultures due to impaired cytochrome P450 (CYP) activity. To this end, hepatic organoids would offer an excellent platform on which to perform chemical-induced hepatotoxicity prediction. Recently, [@B85] have found that hepatic organoids can express Phase I drug metabolism CYP enzymes and Phase II detoxification enzymes. Specifically, CYP1A2 and CYP3A4 were induced following omeprazole treatment in hepatic organoid culture. In addition, CYP3A4- and CYP1A2/2E1-mediated hepatotoxic drugs (troglitazone and APAP, respectively) were analyzed in 2D hepatocyte and organoid cultures. Based on cell viability experiments following exposure to hepatotoxic drugs at clinically relevant concentrations, hepatic organoids exhibited higher sensitivity than 2D hepatocytes. In particular, the toxic concentration of trovafloxacin (a broad-spectrum antibiotic) was approximately 50-fold higher in 2D hepatocytes ([@B85]). In conclusion, organoid-based hepatotoxicity analysis proves beneficial for drug screening studies and early prediction of chemical-induced liver injury. Alternatively, our recent findings suggest that iPSC-derived hepatic organoids can be readily cultured for many generations (at least 48 passages) and continue to preserve hepatic functions, rendering this model suitable for long-term preclinical hepatotoxicity screening studies ([@B2]).

Biobanking {#S4.SS6}
----------

The organoid models will also serve as a renewable resource via cryopreserved biobanks of healthy and diseased human organoids ([@B124]). Today, these "Living Biobanks" are becoming increasingly attractive to researchers in academia and industry for various purposes, especially those related to the development of innovative therapeutic strategies, the identification of novel diagnostic markers, and the development of individualized patient treatment plans. Recently, the Human Cancer Models Initiative (HCMI), was established as an international collaboration between the US National Cancer Institute (NCI), Cancer Research UK (CRUK), the Wellcome Sanger Institute (WSI), and the Hubrecht Organoid Technology (The HUB). As part of the pilot phase, by using cutting-edge technologies, the HCMI aims to generate, clinically annotate, and genetically characterize around 1,000 next-generation cancer cell/organoid models from patient tumors^[2](#footnote2){ref-type="fn"}^. The overall goal of the HCMI is to advance cancer research by providing the research community with a large collection of readily accessible cancer cell models and all the necessary resources, including consent forms and standardized protocols, used for model development. These cancer models can then be utilized to perform basic and translational cancer research and contribute to drug target discovery, the identification of novel disease-specific biomarkers, and the development of preventive as well as therapeutic strategies for personalized medicine.

Gene Therapy {#S4.SS7}
------------

Targeted gene therapy has been used with great success to repair or inactivate mutations of genetic diseases in animal or *in vitro* cell culture models. In the near future, many efforts will likely be devoted to combining modern genome editing tools with organoid technologies *in vitro* to generate healthy isogenic organoids by repairing genetic defects in patient-derived organoids. Hopefully, these technologies could potentially be exploited to treat patients with life-threatening and otherwise incurable diseases, granted that the grafts are accepted by the recipient tissue without any immune rejection. As an example, a disease-causing mutation has recently been reverted to wild-type via CRISPR-Cas9 in patient-derived organoids from Alagille syndrome, and the phenotype of the disease was successfully rescued *in vitro* ([@B47]). We have reason to believe that whenever the genome editing technologies become fully applicable for clinical practice with regard to safety and efficiency, organoid technologies will also become feasible for such therapies.

Transplantation {#S4.SS8}
---------------

Functional organoids are promising alternatives for cell and whole organ transplantations, as they can be produced from isogenic self-tissues. Using iPSC technologies, it is also possible to generate HLA-matched tissue-specific organoids from readily accessible tissue biopsies. Indeed, the capacity of *in vitro* cultured organoids to repair diseased or damaged tissue *in vivo* has been demonstrated by studies reporting functional engraftment of orthotopically transplanted organoids in the kidney ([@B125]), liver ([@B119]; [@B55]; [@B52]; [@B2]), and brain ([@B74]). As a final remark, these transplantable organoids should be produced following method validation, a key element in proving the quality and reliability of the product being developed, under Good Manufacturing Laboratory (GMP) compliance.

Limitations {#S5}
===========

Even though the volume of literature on this topic has exploded incredibly over the course of the last few years (named [@B81]), the organoid technology remains an imperfect cell culture model, and various challenges and limitations need to be addressed to improve organoid models. Currently, the time required for tissue maturation and for organoid outgrowth is a major limitation, increasing the cost of organoid generation, particularly for certain organoids such as retina, brain, and liver, where early progenitor/undifferentiated cells are present in the structure. Other limitations of organoid culture are the lack of vascularization, which is essential for nutrient exchange, and the lack of interaction with other cell types of the native microenvironment, such as immune and neural cells. Moreover, current organoid cultures fail to recapitulate the complex network between different body systems, which is a limiting factor in studying the coordinated function and crosstalk between distinct organs. In addition, organoid cultures are heterogeneous, with no reliable means of synchronizing size, shape, and viability. This, unfortunately, leads to complications in systematic data analysis and study design ([@B37]). Additionally, Matrigel is often a critical component of organoid culture. Matrigel derived from mouse-sarcoma is the major practical barrier against the generation of human-transplantable organoids. Furthermore, organoid culture is unable to mimic *in vivo* growth factor/signaling gradients in matrix, a potential limitation for organoid growth from certain tissues. To address these challenges and overcome these limitations, biomimetic scaffolds based on either synthetic polymers or natural macromolecules need to be constructed, and protocols regarding media recipes need to be modified.

Discussion {#S6}
==========

Organoids are one of the most accessible 3D cultures of cells and organ fragments, in which the self-organizing properties of stem cells and their differentiated progeny are orchestrated to establish physiologically relevant models of human tissues *in vitro*. These rapidly evolving models have a wide range of applications, such as providing a source of functional healthy and diseased human tissue from limited amounts of starting material for studying tissue-specific biological processes, analyzing the dynamics of stem cell behavior, and performing drug screening and disease modeling at near-physiological conditions, thus maximizing their potential to bridge the gap between basic research and translational medicine. Increasing interest in organoid technologies will ensure that these models are accessible to a broad range of academic and clinical scientists. In combination with a more defined ECM, it can be foreseen that a highly accurate and reproducible culture model could emerge and overcome existing constraints that prevent the transition from bench to bedside.

Over the past decade, liver organoids have proved the most powerful next-generation cell culture system in modeling liver diseases and are becoming an increasingly viable option for disease- or patient-specific therapeutic strategies in personalized liver medicine.
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